Financial Performance - The company achieved operating revenue of 891 million RMB, an increase of 16.30% year-on-year[5]. - The net profit attributable to shareholders was -71.76 million RMB, a decrease of 735.92% year-on-year[5]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was -69.55 million RMB, a decrease of 161.94% year-on-year[5]. - The significant decline in net profit was primarily due to a goodwill impairment loss of 31.82 million RMB related to the acquisition of Zhejiang Haichang Pharmaceutical Co., Ltd.[5]. - The net cash flow from operating activities decreased by 54.26% to ¥58,460,838.93, down from ¥127,812,757.45 in 2022[19]. - The basic earnings per share dropped to -¥0.15, a decrease of 850.00% compared to ¥0.02 in 2022[19]. - The net assets attributable to shareholders decreased by 7.08% to ¥1,650,617,396.86 from ¥1,776,339,641.85 in 2022[19]. - The company reported a total non-operating loss of -¥2,210,955.34 for 2023, compared to a gain of ¥37,834,555.36 in 2022[26]. - The company reported a total revenue of 1,070.7 million, with a net profit of 58.8 million, indicating a significant performance in the fiscal year[121]. Research and Development - R&D investment increased by 22.62% year-on-year, amounting to an additional 22.56 million RMB[5]. - The company has integrated its R&D resources by merging Beilu Research Institute with Beijing Aipakesi Pharmaceutical R&D Co., enhancing efficiency and professionalism in product development[38]. - The total R&D expenditure for 2023 was CNY 122,328,869.24, representing 13.73% of operating revenue, an increase from 13.03% in 2022[69]. - The number of R&D personnel increased by 30.64% to 226, with a higher proportion holding bachelor's degrees[69]. - The company is currently reviewing several new products, including gadobutrol injection and sodium calcium edetate, aimed at enhancing market competitiveness[68]. Product Development and Sales - The company plans to continue expanding its product lines in various fields, including contrast agents, central nervous system, endocrine, digestive system, and cardiovascular areas[5]. - The company's contrast agent products achieved sales revenue of 535.24 million yuan, a year-on-year increase of 4.59%[33]. - The strategic product, Jiuwei Zhenxin Granules, generated sales revenue of 140.78 million yuan, reflecting a year-on-year growth of 13.10%[34]. - Sales revenue from diabetes medications, including Glimepiride and Repaglinide, reached 94.55 million yuan, marking a significant year-on-year increase of 59.02%[35]. - The raw materials segment, particularly for gadolinium and iodine contrast agents, reported sales revenue of 221.75 million yuan, up 54.79% year-on-year[37]. - The overseas market expansion resulted in total revenue of 115 million yuan, a remarkable year-on-year growth of 132.98%[37]. Market Strategy and Expansion - The company is actively expanding its sales channels, including e-commerce and retail, to enhance the influence of its "anti-anxiety traditional Chinese medicine" brand[33]. - The company aims to strengthen its market position by focusing on segmented fields and increasing market share through strategic marketing adjustments[30]. - The company is focusing on expanding its overseas market presence, with a continuous increase in foreign sales revenue[93]. - The company is pursuing a dual-driven business model of "chemical drugs + traditional Chinese medicine" to stimulate growth and enhance profitability[94]. Corporate Governance and Compliance - The company has maintained compliance with corporate governance standards, aligning with the requirements of the Company Law and the Shenzhen Stock Exchange regulations, ensuring no significant discrepancies exist[115]. - The company’s governance structure has been continuously improved, enhancing operational compliance and governance levels[115]. - The company has established a robust internal control and management system, contributing to its stable operations and performance[137]. - The company has implemented various control measures, including separation of incompatible duties and budget control[151]. - The company has received multiple environmental approvals for its projects, including the high-end intelligent injection workshop and R&D center, demonstrating compliance with environmental regulations[160]. Environmental Responsibility - The company has established a comprehensive safety and environmental protection system to mitigate risks associated with production and environmental impact[99]. - The company has implemented various environmental protection measures in line with national and local regulations, reflecting its commitment to sustainability[158]. - The company has undergone multiple environmental impact assessments and received approvals for its projects since 1999, showcasing a long-standing compliance history[159]. - The company has established emergency response plans for environmental incidents, with annual drills conducted since 2021[168]. Human Resources and Talent Development - The company aims to enhance its talent development and management capabilities to achieve its strategic goals, including becoming one of the top 100 pharmaceutical manufacturers in China[142]. - The company plans to implement various training programs in 2024 to enhance employee skills and support organizational development[142]. - The company has established a mentorship program to improve operational staff's business skills and responsibilities[142]. - The total remuneration for directors, supervisors, and senior management during the reporting period amounted to CNY 9.662 million[131]. Investment and Financial Management - The company has committed a total of 50,000 million CNY for investment projects, with 37,580.63 million CNY actually utilized by the end of the reporting period, representing a utilization rate of 75.16%[86]. - The company has not engaged in any securities or derivative investments during the reporting period[81][82]. - The company has proposed to change the use of part of the raised funds and to permanently supplement working capital with surplus funds from terminated projects[138]. - The company completed the dividend distribution for the 2022 fiscal year on May 25, 2023, and adjusted the convertible bond conversion price to CNY 8.68 per share[198]. Risk Management - The company emphasizes the importance of risk awareness regarding future plans and performance forecasts[5]. - The company has detailed various risks and countermeasures in its management discussion and analysis section[6]. - The company is actively monitoring industry policy changes and adjusting its operational strategies accordingly to mitigate risks from regulatory changes[95]. - Strengthening internal control management to effectively mitigate operational risks will be a key focus for the company in 2024[107].

股票代码：300016 股票简称：北陆药业 公告编号：2024-023 债券代码：123082 债券简称：北陆转债 北京北陆药业股份有限公司 关于拟续聘会计师事务所的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 北京北陆药业股份有限公司（以下简称"公司"）于 2024 年 4 月 18 日召 开第八届董事会第十七次会议、第八届监事会第十三次会议，审议通过了《关 于续聘 2024 年度审计机构的议案》，拟续聘致同会计师事务所（特殊普通合伙） （以下简称"致同所"）为公司 2024 年度审计机构。现将有关事项公告如下： 一、拟续聘会计师事务所的基本信息 （一）机构信息 1、基本信息 会计师事务所名称：致同会计师事务所（特殊普通合伙） 成立日期：1981 年 注册地址：北京市朝阳区建国门外大街 22 号赛特广场五层 首席合伙人：李惠琦 执业证书颁发单位及序号：北京市财政局 NO 0014469 截至 2023 年末，致同所从业人员近六千人，其中合伙人 225 名，注册会 计师 1,364 名，签署过证券服务业务审计报告的注册会计师超过 400 人。 券业务收 ...

北京北陆药业股份有限公司 营业收入扣除情况表 专项核查报告 致同会计师事务所（特殊普通合伙） 目 录 专项核查报告 公司 2023 年度营业收入扣除情况表及说明 1-2 致同会计师事务所（特殊普通合伙） 中国北京 朝阳区建国门外大街 22 号 赛特广场 5 层 邮编 100004 电话 +86 10 8566 5588 传真 +86 10 8566 5120 www.grantthornton.cn 北京北陆药业股份有限公司 营业收入扣除情况表专项核查报告 致同专字（2024）第 110A008426 号 北京北陆药业股份有限公司全体股东： 我们接受委托，在审计了北京北陆药业股份有限公司（以下简称"北陆 药业公司"）2023 年 12 月 31 日的合并及公司资产负债表，2023 年度的合并及 公司利润表、合并及公司现金流量表、合并及公司股东权益变动表以及财务 报表附注的基础上，对后附的《北陆药业公司 2023 年度营业收入扣除情况表 及说明》（以下简称"营业收入扣除情况表"）进行了专项核查。 按照《深圳证券交易所创业板股票上市规则》（以下简称"上市规则"） 和《深圳证券交易所创业板上市公司自律监管指南第 1 ...

| 股票代码：300016 | 股票简称：北陆药业 | 公告编号：2024-025 | | --- | --- | --- | | 债券代码：123082 | 债券简称：北陆转债 | | 北京北陆药业股份有限公司 董事会关于募集资金年度存放与使用情况的专项报告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 根据《上市公司监管指引第2号——上市公司募集资金管理和使用的监管要 求（2022年修订）》和《深圳证券交易所上市公司自律监管指引第2号—创业板上 市公司规范运作》有关规定，现将本公司2023年度募集资金存放与使用情况说明 如下： 一、募集资金基本情况 （一）实际募集资金金额、资金到位时间 经中国证券监督管理委员会《关于同意北京北陆药业股份有限公司向不特定 对象发行可转换公司债券注册的批复》（证监许可〔2020〕2810号）核准，公司 向社会公开发行面值不超过人民币500,000,000.00元的可转换公司债券。根据《北 京北陆药业股份有限公司向不特定对象发行可转换公司债券发行公告》，公司债 券发行面值50,000万元，每张面值为人民币100元，共计500万 ...

债券代码：123082 债券简称：北陆转债 关于部分募集资金投资项目延期的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 北京北陆药业股份有限公司（以下简称"公司"）于 2024 年 4 月 18 日召 开第八届董事会第十七次会议、第八届监事会第十三次会议，审议通过了《关 于部分募集资金投资项目延期的议案》，同意公司在募投项目实施主体、实施 地点、投资用途、投资总额不变的情况下将"沧州三期原料生产项目"达到预 定可使用状态的日期调整至 2024 年 9 月 30 日。本事项在董事会审批权限内， 无需提交股东大会审议。现将具体情况公告如下： 一、募集资金基本情况 经中国证券监督管理委员会（以下简称"中国证监会"）《关于同意北京 北陆药业股份有限公司向不特定对象发行可转换公司债券注册的批复》（证监 许可〔2020〕2810 号）同意，公司向社会公开发行面值不超过人民币 500,000,000.00 元的可转换公司债券。根据《北京北陆药业股份有限公司向不 特定对象发行可转换公司债券发行公告》，本期公司债券发行面值 50,000 万 元，每张面值为人民币 100 ...

董事会审计委员会对会计师事务所 2023 年度 履行监督职责的情况报告 根据《中华人民共和国公司法》《中华人民共和国证券法》《上市公司治 理准则》《国有企业、上市公司选聘会计师事务所管理办法》等有关规定和要 求，北京北陆药业股份有限公司（以下简称"公司"）董事会审计委员会本着 勤勉尽责的原则，恪尽职守，认真履职。现将董事会审计委员会对致同会计师 事务所（特殊普通合伙）（以下简称"致同所"）2023 年度履行监督职责情况 汇报如下： 一、2023年年审会计师事务所基本情况 （一）会计师事务所基本情况 会计师事务所名称：致同会计师事务所（特殊普通合伙） 成立日期：1981 年 注册地址：北京市朝阳区建国门外大街 22 号赛特广场五层 首席合伙人：李惠琦 执业证书颁发单位及序号：北京市财政局 NO 0014469 截至 2023 年末，致同所从业人员近六千人，其中合伙人 225 名，注册会 计师 1,364 名，签署过证券服务业务审计报告的注册会计师超过 400 人。 致同所 2022 年度业务收入 26.49 亿元，其中审计业务收入 19.65 亿元，证 券业务收入 5.74 亿元。2022 年度上市公司审计客户 ...

2023年度独立董事述职报告 各位股东及股东代表： （一）基本情况 本人曹纲，男，1979年出生，中国国籍，无境外永久居留权，本科，注册 会计师、税务师、经济师、资产评估师。现任公司独立董事、中勤万信会计师 事务所（特殊普通合伙）天津分所合伙人/审计二部总经理；兼任天津市和平投 资发展集团有限公司董事、天津东疆港产城投资集团有限公司董事、天津东疆 发展集团有限公司董事；曾任天津市中和信诚会计师事务所审计经理。 （二）独立性说明 本人在担任公司独立董事期间，未在公司担任除独立董事以外的任何职务， 也未在公司主要股东公司担任任何职务，与公司以及主要股东之间不存在妨碍 本人进行独立客观判断的关系，不存在影响独立董事独立性的情况，符合《上 1 市公司独立董事管理办法》、《深圳证券交易所上市公司自律监管指引第2号 ——创业板上市公司规范运作》等法律、法规、规范性文件及《公司章程》、 《独立董事工作制度》中关于独立董事独立性的相关要求。 二、2023年度履职概况 本人作为北京北陆药业股份有限公司（以下简称"公司"）的独立董事， 在任职期间严格按照《公司法》、《证券法》、《上市公司治理准则》、《上 市公司独立董事管理办法》 ...

Financial Performance - The company's operating revenue for Q1 2024 was ¥207,506,078.84, representing a year-on-year increase of 10.35% compared to ¥188,036,687.69 in the same period last year[3] - The net profit attributable to shareholders decreased by 8.35% to ¥11,526,165.00 from ¥12,576,111.47 in the previous year, while the net profit excluding non-recurring gains and losses increased by 32.95% to ¥11,446,351.32[3] - Operating profit for Q1 2024 reached CNY 15,862,651.22, up 54.5% from CNY 10,281,712.65 in Q1 2023[27] - Net profit for Q1 2024 was CNY 11,621,240.12, representing a 14.1% increase from CNY 10,184,088.91 in the previous year[29] - The company reported a total comprehensive income of CNY 11,621,240.12 for Q1 2024, compared to CNY 10,184,088.91 in the previous year, reflecting a growth of 14.1%[29] Cash Flow - The net cash flow from operating activities was ¥35,344,060.75, a slight decrease of 1.40% from ¥35,846,735.41 in the previous year[3] - The company reported a net cash flow from operating activities of CNY 35,344,060.75, slightly down from CNY 35,846,735.41 in Q1 2023[32] - The net cash flow from investing activities was negative at -¥288,782,400.00, a decrease of 40.37% year-on-year, mainly due to increased cash payments for financial products and equity acquisition intentions[11] - Net cash flow from investment activities was -$288,782,387.03, compared to -$205,732,699.81 previously[34] - Cash inflow from financing activities amounted to $84,000,000.00, up from $69,800,000.00 in the prior period[34] - Cash outflow from financing activities was $47,308,364.84, significantly higher than $8,201,162.06 previously[34] - Net cash flow from financing activities was $36,691,635.16, a decrease from $61,598,837.94 in the previous period[34] - The net increase in cash and cash equivalents was -$216,530,309.24, compared to -$108,716,024.53 previously[34] - The ending balance of cash and cash equivalents was $515,204,730.85, down from $628,227,882.71 in the prior period[34] Assets and Liabilities - Total assets at the end of the reporting period were ¥2,869,853,260.93, reflecting a 1.79% increase from ¥2,819,424,047.96 at the end of the previous year[5] - The company's total assets amounted to approximately CNY 2.87 billion, an increase from CNY 2.82 billion at the beginning of the period, reflecting a growth of about 1.5%[21] - The company's total liabilities increased from CNY 1.12 billion to CNY 1.14 billion, indicating a rise of approximately 1.8%[21] - Total liabilities increased to CNY 1,070,552,237.60, compared to CNY 1,033,111,812.55 in the previous year, reflecting a growth of 3.6%[26] - The company’s total current liabilities increased from CNY 175.56 million to CNY 192.06 million, an increase of approximately 9.4%[21] - The company’s short-term borrowings rose from CNY 175.56 million to CNY 192.06 million, reflecting an increase of about 9.4%[21] Equity and Investments - The company's total equity reached CNY 1,799,301,023.33, an increase from CNY 1,786,312,235.41, marking a growth of 0.7%[26] - The company’s long-term equity investments slightly decreased from CNY 200.92 million to CNY 197.03 million, a decline of about 1.4%[24] - Long-term borrowings rose to CNY 152,550,000.00, up from CNY 129,950,000.00, indicating a 17.3% increase year-over-year[26] - The company has made a payment of ¥20,000,000.00 for the equity acquisition intention of an 80% stake in Chengde Tianyuan Pharmaceutical Co., Ltd., indicating ongoing market expansion efforts[10] - The company completed the acquisition of 80% equity in Chengde Tianyuan Pharmaceutical Co., Ltd., as approved by the board on April 16, 2024[18] Inventory and Receivables - Accounts receivable decreased from CNY 185.04 million to CNY 166.81 million, a reduction of about 9.8%[21] - The company reported an increase in inventory from CNY 244.86 million to CNY 251.76 million, which is an increase of approximately 2.8%[21] - The company reported a significant increase in prepaid accounts, which rose by 195.94% to ¥21,328,900.00, primarily due to advance payments for raw material purchases[10] Research and Development - Research and development expenses for Q1 2024 were CNY 13,889,933.57, a decrease of 18.8% from CNY 17,042,221.17 in the same quarter last year[27] Other Information - The weighted average return on equity was 0.70%, slightly down from 0.71% in the previous year[3] - The basic earnings per share for Q1 2024 was CNY 0.0235, down from CNY 0.0256 in Q1 2023[29] - The company has not audited the first quarter report[36]

北京北陆药业股份有限公司 控股股东及其关联人占用资金情况专项公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 北京北陆药业股份有限公司（以下简称"公司"、"北陆药业"）2023 年度 审计机构致同会计师事务所（特殊普通合伙）（以下简称"致同所"）对公司 2023 年度非经营性资金占用及其他关联资金往来情况进行了审核，并出具了 专项报告。具体内容公告如下： 一、关于控股股东及其关联人占用资金情况专项说明 股票代码：300016 股票简称：北陆药业 公告编号：2024-027 债券代码：123082 债券简称：北陆转债 致同会计师事务所（特殊普通合伙）出具了《关于北京北陆药业股份有限 公司非经营性资金占用及其他关联资金往来的专项说明》（致同专字（2024） 第 110A008422 号）。根据中国注册会计师执业准则审计了北陆药业公司 2023 年 12 月 31 日的合并及公司资产负债表，2023 年度合并及公司利润表、合并 及公司现金流量表、合并及公司股东权益变动表和财务报表附注，并出具了致 同审字（2024）第 110A012740 号无保留意见审计报告。 ...

二○二四年四月二十二日 1 董事会对独立董事独立性评估的专项意见 根据《上市公司独立董事管理办法》、《深圳证券交易所创业板股票上市 规则》、《深圳证券交易所上市公司自律监管指引第2号——创业板上市公司 规范运作》等要求，北京北陆药业股份有限公司（以下简称"公司"）董事会， 就公司在任独立董事王英典、郑斌、曹纲的独立性情况进行评估并出具如下专 项意见： 经核查，公司独立董事王英典、郑斌、曹纲的任职经历以及签署的相关 自查文件，上述人员未在公司担任除独立董事以外的任何职务，亦未在公司 主要股东公司担任任何职务，与公司以及主要股东之间不存在利害关系或其 他可能妨碍其进行独立客观判断的关系。因此，公司三名独立董事符合《上 市公司独立董事管理办法》、《深圳证券交易所上市公司自律监管指引第2号 ——创业板上市公司规范运作》等规定中对独立董事独立性的相关要求。 北京北陆药业股份有限公司 董事会 ...